On September 5, 2023 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that it will be presenting a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting, taking place in Rotterdam, September 21-24, 2023 (Press release, Kintara Therapeutics, SEP 5, 2023, View Source [SID1234634896]). The presentation will include data from its lead program, VAL-083, for the treatment of recurrent glioblastoma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation are as follows:
Topic Section: Clinical neuro-oncology
Presentation Time: Saturday, September 23, 2023 – 5:15 p.m. to 6:45 p.m. CEST
Title: Phase 2 Study of VAL-083 and Radiotherapy in Newly Diagnosed MGMT-unmethylated GBM: Case Study Reports
Abstract/ Poster Number: P11.41.B
Presenter: Dr. Zong-ping Chen, Professor & Chairman of Department of Neurosurgery/Neuro-oncology of Sun Yat-sen University Cancer Center, Guangzhou, China & Dr. John Langlands, Kintara Therapeutics Inc, San Diego, CA
Abstracts will be published on the website of Neuro-Oncology on September 7, 2023.
Kintara recently hosted an event featuring key opinion leaders Patrick Y. Wen, M.D. (Harvard Medical School) and John de Groot, M.D. (UCSF Health) discussing the current treatment landscape for patients suffering from GBM along with Kintara’s potential treatment solution with VAL-083. More information about VAL-083 and its potential as a first-in-class small molecule chemotherapeutic for glioblastoma (GBM), can be found on the replay of that event here.